SG Americas Securities LLC Raises Holdings in Perrigo Company plc (NYSE:PRGO)

SG Americas Securities LLC increased its stake in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 152.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 67,947 shares of the company's stock after buying an additional 41,079 shares during the quarter. SG Americas Securities LLC's holdings in Perrigo were worth $1,905,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Headlands Technologies LLC increased its stake in shares of Perrigo by 1,942.0% in the 4th quarter. Headlands Technologies LLC now owns 1,409 shares of the company's stock worth $36,000 after acquiring an additional 1,340 shares during the last quarter. Parallel Advisors LLC increased its position in Perrigo by 176.9% during the first quarter. Parallel Advisors LLC now owns 1,714 shares of the company's stock worth $48,000 after purchasing an additional 1,095 shares during the last quarter. Central Pacific Bank Trust Division raised its stake in Perrigo by 50.0% during the first quarter. Central Pacific Bank Trust Division now owns 3,000 shares of the company's stock worth $84,000 after purchasing an additional 1,000 shares during the period. GAMMA Investing LLC boosted its holdings in Perrigo by 91.9% in the 1st quarter. GAMMA Investing LLC now owns 3,685 shares of the company's stock valued at $103,000 after purchasing an additional 1,765 shares during the last quarter. Finally, Venturi Wealth Management LLC grew its stake in shares of Perrigo by 97.8% in the 4th quarter. Venturi Wealth Management LLC now owns 4,215 shares of the company's stock valued at $108,000 after buying an additional 2,084 shares during the period. Institutional investors and hedge funds own 95.91% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Perrigo from a "hold" rating to a "buy" rating in a research report on Saturday, May 24th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $33.00.

Perrigo Trading Up 0.2%

NYSE PRGO traded up $0.06 during trading hours on Monday, reaching $26.71. The company had a trading volume of 1,068,990 shares, compared to its average volume of 1,478,979. Perrigo Company plc has a 1-year low of $23.14 and a 1-year high of $30.93. The company has a current ratio of 2.56, a quick ratio of 1.77 and a debt-to-equity ratio of 0.94. The stock has a 50-day moving average of $26.02 and a 200 day moving average of $26.11. The stock has a market capitalization of $3.67 billion, a P/E ratio of -22.83 and a beta of 0.46.

Perrigo (NYSE:PRGO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.56 by $0.04. The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.09 billion. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. Perrigo's revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the business posted $0.29 EPS. As a group, research analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 17th. Shareholders of record on Friday, May 30th will be issued a dividend of $0.29 per share. The ex-dividend date is Friday, May 30th. This represents a $1.16 dividend on an annualized basis and a yield of 4.34%. Perrigo's dividend payout ratio (DPR) is presently -88.55%.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.